<DOC>
	<DOCNO>NCT00504244</DOCNO>
	<brief_summary>This study design explore use myfortic ® patient active lupus erythematosus . Similar drug class increasingly use organ transplantation autoimmune disease . With establish safety profile myfortic ® allo-transplantation already exist data mycophenolate mofetil autoimmune disease , study help demonstrate beneficial effect myfortic ® lupus activity . The aim study show decrease disease activity myfortic ® compare standard maintenance therapy azathioprine .</brief_summary>
	<brief_title>Myfortic Versus Azathioprine Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) complex potentially life-threatening disease affect 40 per 10,000 people general population ( Mills 1994 , Brown &amp; Schrieber 1996 ) . SLE chronic inflammatory disease characterize auto-antibody overproduction distinct immunological abnormality ( Boumpas , et al 1995 , Mohan &amp; Datta 1995 ) . It may affect skin , joint , lung , heart , serous membrane , nervous system organ . Improvements treatment last decade increase 10-year survival rate Western country 90 % , 20-year survival rate nearly 70 % also report ( Abu-Shakra , et al 1995 ) . Newer treatment strategy include use novel immunosuppressive agent , mycophenolate mofetil ( MMF ) . MMF widely use solid-organ transplantation ( Sollinger 1995 , The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group 1996 ) . MMF also use increasingly autoimmune disease ( e.g. , dermatomyositis , primary glomerular disease psoriasis ( Epinette , et al 1987 , Gelber , et al 2000 , Choi , et al 2002 ) ) . MMF morpholinoethylester prodrug mycophenolic acid ( MPA ) . After oral administration MMF well absorbed rapidly hydrolyze MPA . MPA noncompetitive inhibitor inosine monophosphate ( IMP ) dehydrogenase ( DH ) . Inhibition IMPDH lead depletion deoxyguanosine triphosphate consequent decrease level substrate require DNA polymerase activity . This result inhibition DNA production cell proliferation . T B cell dependent de novo pathway purine synthesis alternative salvage pathway unavailable . Thus , MPA selective inhibitor lymphocyte proliferation , especially activate lymphocyte ( Allison &amp; Eugui 2000 ) . A limited number clinical study perform study efficacy MMF treatment SLE . Most study involve treatment nephritis . Chan , et al ( 2000 ) show combination MMF prednisolone effective regimen cyclophosphamide prednisolone follow azathioprine prednisolone . Azathioprine MMF maintenance therapy compare cyclophosphamide therapy ( Contreras , et al 2004 ) appear efficacious safe long-term therapy i.v . cyclophosphamide . In study , also note patient treated MMF receive low dos corticosteroid maintenance therapy compare patient treated azathioprine . Recent report suggest MMF may also effective systemic lupus without severe renal involvement . ( Pisoni , et al 2005 ) Yet , superiority azathioprine patient group establish . Own observation show approximately 50 % patient SLE treat azathioprine least evidence lupus activity . The aim study show decrease lupus activity patient treat myfortic ® compare therapy azathioprine . Data gather may useful plan future development indication This 12 month , multi-center , 2-treatment arm , parallel-group , randomize , open label study patient systemic lupus erythematosus currently azathioprine . The patient randomize one follow two treatment group : - Maintenance previous therapy include azathioprine . - Switch myfortic ® base regimen : myfortic ® ( dose 1440mg/day ) A total 48 patient ( 24 patient per arm ) fulfil inclusion/exclusion criterion enrol study approximately 5 center Netherlands . Screening evaluation assessment perform period inform consent sign patient randomization patient ( Baseline , Day 1 ) . Visits schedule Baseline , Weeks 2 , 4 , 12 , Months 6 , 9 12 . The final analysis perform last patient reach 12 month study . The following efficacy variable obtain record : - Disease activity index measure SLEDAI - Disease activity index measure BILAG ( numerical score ) - ( Average ) daily dose prednisone ( mg/kg/day ) . The dose measured patient start study whole duration study . - Damage index measure SLICC/ACR - Serum creatinine - Creatinine clearance - Urine protein : creatinine ratio</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Males female , age 18 year Patients meet diagnostic criterion SLE ( Appendix 2 ) , accord ACR guideline ( include screen antidsDNA ( antibody native DNA abnormal titer ) ) SLEDAI &gt; 6 Patients treated maintenance therapy include azathioprine . Patients willing able participate study write informed consent obtain Creatinine clearance &lt; 20ml/min Patients clinically significant infection Patients know hypersensitivity myfortic ® drug similar chemical structure Patients history malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Patients SLE active CNS manifestation past history SLE CNS complication ( e.g . psychosis , grand mal seizure ) Patients receive prior therapy mycophenolic acid ( MPAs ) ( e.g . MMF ) Patients receive investigational drug within four week prior study entry Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>SLE</keyword>
	<keyword>SLEDAI</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>Myfortic</keyword>
</DOC>